CRY News and Press, CryoLife Inc. From 04/07/21

CryoLife to Participate in 20th Annual Needham Virtual Healthcare Conference PR Newswire ATLANTA , April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will par...

David Einhorn's 13F stock portfolio value increased from $1.22B to $1.66B this quarter. Greenlight increased Atlas Air Worldwide, Teck Resources, and Resideo Technologies while reducing AerCap Holdings, Chemours, and NCR Corp. during the quarter. The largest three positions are at...

The following slide deck was published by CryoLife, Inc. in conjunction with this event. For further details see: Cryolife (CRY) Investor Presentation - Slideshow

CryoLife to Participate in Oppenheimer 31st Annual Virtual Healthcare Conference PR Newswire ATLANTA , March 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced t...

Image source: The Motley Fool. Cryolife Inc (NYSE: CRY) Q4 2020 Earnings Call Feb 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cryolife Inc (CRY) Q4 2020 Earnings Call Transcript

CryoLife, Inc. (CRY) Q4 2020 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Lynn Lewis – Founder and Chief Executive Officer-Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief Financial Officer Conference Call Participants ...

CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results PR Newswire ATLANTA , Feb. 11, 2021 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved total revenues of $67.9 million in the fourth quarter 20...

CryoLife Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2020 Financial Results PR Newswire ATLANTA , Jan. 28, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company...

CryoLife has a resilient portfolio mix that is bolstered by upcoming regulatory catalysts. The company has decent upside potential through operations, however, this may already be reflected in valuations. Although we are long CRY shares, the company shouldn't command a premium, bu...

CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress PR Newswire ATLANTA, Nov. 19, 2020 ATLANT...